Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 4/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11320636 | 0.97 | PRCP (0.41) | PRCPKCNH2 | |
| SCHEMBL11319371 | 0.87 | PRCP (0.45) | PRCPKCNH2 | |
| SCHEMBL10123964 | 0.84 | PRCP (0.51) | PRCP | |
| SCHEMBL11317687 | 0.83 | PRCP (0.42) | PRCP | |
| SCHEMBL12903304 | 0.81 | PRCP (0.37) | PRCP | |
| SCHEMBL12903293 | 0.79 | PRCP (0.42) | PRCP | |
| SCHEMBL12247797 | 0.78 | KCNH2 (0.51) | PRCPKCNH2CYP3A4CYP2C9 | |
| SCHEMBL12247799 | 0.76 | PRCP (0.50) | PRCPCYP3A4CYP2C9 | |
| SCHEMBL10121395 | 0.76 | CYP3A4 (0.52) | PRCPKCNH2CYP3A4CYP2C9 | |
| SCHEMBL10121311 | 0.76 | PRCP (0.53) | PRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8221737-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-07-17 | — | — | US | disclosed |
| US-20100316607-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100316607-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | PRCP 275/4885KCNH2 3887/4885CYP3A4 204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.